Evidence map›Paper›PMID 36950378›Full record

ArticleCell genomics2023

The Foundational Data Initiative for Parkinson Disease: Enabling efficient translation from genetic maps to mechanism.

Elisangela Bressan, Xylena Reed, Vikas Bansal, Elizabeth Hutchins, Melanie M Cobb, Michelle G Webb, Eric Alsop, Francis P Grenn, Anastasia Illarionova, Natalia Savytska and 33 more

Full text read
In one paragraph

Article in Cell genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors.

Elisangela BressanGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Xylena ReedLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Vikas BansalGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Elizabeth HutchinsDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Melanie M CobbCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA, USA.
Michelle G WebbDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, 1450 Biggy Street, Los Angeles, CA, USA.
Eric AlsopDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Francis P GrennLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Anastasia IllarionovaGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Natalia SavytskaGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Ivo ViolichDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, 1450 Biggy Street, Los Angeles, CA, USA.
Stefanie BroeerGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Noémia FernandesGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Ramiyapriya SivakumarDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, 1450 Biggy Street, Los Angeles, CA, USA.
Alexandra BeilinaLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Kimberley J BillingsleyLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Joos BerghausenLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Caroline B PantazisLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Vanessa PitzLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Dhairya PatelLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Kensuke DaidaLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Bessie MeechoovetDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Rebecca ReimanDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Amanda Courtright-LimDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Amber LogemannDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Jerry AntoneDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
Mariya BarchCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA, USA.
Robert KitchenMassachusetts General Hospital, Cardiovascular Research Center, Charlestown, MA, USA.
Yan LiProtein/Peptide Sequencing Facility, National Institute of Neurological, Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Clifton L DalgardThe American Genome Center, Uniformed Services University of the Health Sciences, Bethesda, MD, USA.
American Genome Center
Patrizia RizzuGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Dena G HernandezLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Brooke E HjelmDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, 1450 Biggy Street, Los Angeles, CA, USA.
Mike NallsLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
J Raphael GibbsLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Steven FinkbeinerCenter for Systems and Therapeutics, Gladstone Institutes, San Francisco, CA, USA.
Mark R CooksonLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Kendall Van Keuren-JensenDivision of Neurogenomics, The Translational Genomics Research Institute, Phoenix, AZ, USA.
David W CraigDepartment of Translational Genomics, Keck School of Medicine, University of Southern California, 1450 Biggy Street, Los Angeles, CA, USA.
Andrew B SingletonLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Peter HeutinkGerman Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
Cornelis BlauwendraatLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.

Funding

Alpha Synuclein, cellular dysfunction and Parkinson diseaseZIAAG000939 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2009 to 2025
$12.7M
Characterization of Normal Genomic VariabilityZIAAG000932 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2009 to 2024
$11.3M
Genome wide SNP analysis in Parkinson's diseaseZ01AG000949 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW B · 2006 to 2008
$2.6M
Genetic Variants Associated with Alzheimer's disease and Related DementiasZIAAG000931 · NIA · NATIONAL INSTITUTE ON AGING · PI COOKSON, MARK · 2019 to 2025
$1.6M
Retromer dysfunction in amyotrophic lateral sclerosisF31NS101966 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PEREZ-TORRES, EDUARDO JOSE · 2017 to 2019
$111k
Intramural NIH HHS Z01 AG000949NINDS NIH HHS F31 NS101966
6 · The paper itself

Abstract

The Foundational Data Initiative for Parkinson Disease (FOUNDIN-PD) is an international collaboration producing fundamental resources for Parkinson disease (PD). FOUNDIN-PD generated a multi-layered molecular dataset in a cohort of induced pluripotent stem cell (iPSC) lines differentiated to dopaminergic (DA) neurons, a major affected cell type in PD. The lines were derived from the Parkinson's Progression Markers Initiative study, which included participants with PD carrying monogenic PD variants, variants with intermediate effects, and variants identified by genome-wide association studies and unaffected individuals. We generated genetic, epigenetic, regulatory, transcriptomic, and longitudinal cellular imaging data from iPSC-derived DA neurons to understand molecular relationships between disease-associated genetic variation and proximate molecular events. These data reveal that iPSC-derived DA neurons provide a valuable cellular context and foundational atlas for modeling PD genetic risk. We have integrated these data into a FOUNDIN-PD data browser as a resource for understanding the molecular pathogenesis of PD.

Indexed as

dopaminergic neuronsgenetic riskinduced pluripotent stem cellomics single-cell RNA sequencing single-cell ATAC sequencing SNCA LRRK2 GBA1Parkinson disease

Identifiers

PMID36950378
PMCPMC10025424

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read70
identifiers read2
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.